TP53 mutations are significantly more common in patients with advanced breast cancer, high-grade tumors, and aggressive tumors such as the erb-b2 receptor tyrosine kinase 2 (ERBB2)+ subtype. This evidence concerns the gene TP53 and breast carcinoma.